PPAR Research

Published Special Issues


Published Special Issues

PPARs in Viral Disease

Guest Editors
Lawrence Serfaty | Jacqueline Capeau
Status
Published
Publishing date01 Jan 2009
Articles9

Peroxisome Proliferator-Activated Receptor δ, A Target with a Broad Therapeutic Potential for Drug Discovery

Guest Editors
Francine Gregoire
Status
Published
Publishing date01 Dec 2008
Articles7

PPARs: A Double-Edged Sword in Cancer Therapy?

Guest Editors
Dipak Panigrahy | Arja Kaipainen | Mark Kieran | Judah Folkman | Sui Huang
Status
Published
Publishing date01 Sep 2008
Articles58

PPARs in Eye Biology and Disease

Guest Editors
Suofu Qin | Roy Chuck
Status
Published
Publishing date01 Jul 2008
Articles9

Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities

Guest Editors
Francine Gregoire | Anne Miller | Jane Pinaire
Status
Published
Publishing date01 Jul 2008
Articles10

PPARs in Neuroinflammation

Guest Editors
Michael Racke | Paul Drew
Status
Published
Publishing date01 Jun 2008
Articles12

PPARs/RXRs in Cardiovascular Physiology and Disease

Guest Editors
Brian Finck | Giulia Chinetti | Bart Staels
Status
Published
Publishing date01 Jan 2008
Articles12

PPARs and RXRs in Male and Female Fertility and Reproduction

Guest Editors
Pascal Froment
Status
Published
Publishing date01 Dec 2007
Articles11

PPARs, RXRs, and Stem Cells

Guest Editors
Z. Floyd | Jeffrey Gimble
Status
Published
Publishing date01 Nov 2007
Articles8

PPARs in Lung Biology and Disease

Guest Editors
Theodore Standiford | Jesse Roman
Status
Published
Publishing date01 Sep 2007
Articles10
PPAR Research
 Journal metrics
See full report
Acceptance rate11%
Submission to final decision75 days
Acceptance to publication21 days
CiteScore5.800
Journal Citation Indicator0.720
Impact Factor2.9
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.